• In early July 2026, Herbalife expanded its global Fuel Like Ronaldo campaign with a science-based 4 R post-exercise recovery framework and, separately, Herbalife India launched a Dates Caramel variant of its Formula 1 Nutritional Shake Mix to broaden flavor choice for everyday nutrition.
• Together, these moves underline Herbalife’s effort to anchor its brand more firmly in evidence-informed sports recovery guidance and localized product innovation.
• We’ll now examine how this expanded Fuel Like Ronaldo recovery framework could influence Herbalife’s investment narrative and long-term positioning.

Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Herbalife Investment Narrative Recap

To own Herbalife today, you need to believe in its shift toward science-backed, personalized wellness and the resilience of its distributor-led model, despite high leverage and pressure on margins. The expanded Fuel Like Ronaldo 4 R recovery framework and new India shake flavor are brand-building moves, but they do not materially change the near term focus on stabilizing volume growth and managing debt risk.

Among recent developments, the launch of MultiBurn in 2025 looks most relevant. It highlights Herbalife’s push into science-oriented metabolic health products, which ties directly into the same “evidence-informed wellness” story reinforced by the 4 R recovery guidance. For investors watching catalysts, these kinds of launches sit alongside digital tools and subscription offerings as potential drivers of more recurring, higher quality revenue if customer engagement holds up.

Yet while the brand is leaning harder into science-based messaging, investors should also be aware of growing regulatory scrutiny and how it could...

Herbalife's narrative projects $5.6 billion revenue and $317.3 million earnings by 2029. This requires 2.9% yearly revenue growth and about a $77.5 million earnings increase from $239.8 million today.

Uncover how Herbalife's forecasts yield a $18.33 fair value, a 42% upside to its current price.

Exploring Other Perspectives

The most bearish analysts paint a far tougher picture than the consensus, even before this news, assuming only about 2.8% annual revenue growth and earnings of roughly US$296.7 million by 2029. Compared with the optimism behind campaigns like Fuel Like Ronaldo and products such as MultiBurn, that is a much more cautious read on Herbalife’s ability to turn brand and product innovation into sustained financial progress, and it is worth weighing alongside these newer developments.

Explore 6 other fair value estimates on Herbalife - why the stock might be worth just $12.65!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Herbalife research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Herbalife research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Herbalife's overall financial health at a glance.

Contemplating Other Strategies?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.